Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review.
HLH
IL-1 receptor antagonist
IV anakinra
MAS
cytokine storm
haemophagocytic lymphohistiocytosis
intravenous anakinra
macrophage activation syndrome
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
09
06
2023
received:
24
02
2023
accepted:
12
06
2023
medline:
7
8
2023
pubmed:
22
6
2023
entrez:
21
6
2023
Statut:
ppublish
Résumé
Haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) has a potentially high mortality rate. Anakinra, an interleukin-1 receptor antagonist, is now recommended early in HLH/MAS, with intravenous (IV) use proposed in critically unwell patients. This systematic review establishes the literature relating to IV anakinra in secondary HLH/MAS (sHLH/MAS). We screened Embase, PubMed, and Medline, including all reports of IV anakinra for HLH or MAS. We extracted age, HLH/MAS trigger, continuous infusion or bolus dosing, and survival. Twenty-nine case reports/series identified 87 patients (median age 22 years, range 22 months to 84 years), all with sHLH. Amongst identifiable triggers, 43% were systemic infection, 33% rheumatological, 9% oncological. Children had predominantly a rheumatological trigger (48%), whilst adults were more commonly infection-driven (50%). Overall, rheumatologically triggered disease showed greater survival (83.3%), particularly compared with oncological triggers (42.9%). Children had a greater survival, particularly under 10 years (83%, vs. adults, 63%). Despite IV anakinra recipients likely to be critically unwell, this cohort had similar disease triggers and survival compared to large historical cohorts, and enhances awareness of age and trigger-specific survival patterns. IV anakinra had a wide therapeutic dosing range and tolerability, regardless of trigger, demonstrating substantial utility in severe sHLH/MAS.
Sections du résumé
BACKGROUND
BACKGROUND
Haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) has a potentially high mortality rate. Anakinra, an interleukin-1 receptor antagonist, is now recommended early in HLH/MAS, with intravenous (IV) use proposed in critically unwell patients. This systematic review establishes the literature relating to IV anakinra in secondary HLH/MAS (sHLH/MAS).
METHODS
METHODS
We screened Embase, PubMed, and Medline, including all reports of IV anakinra for HLH or MAS. We extracted age, HLH/MAS trigger, continuous infusion or bolus dosing, and survival.
RESULTS
RESULTS
Twenty-nine case reports/series identified 87 patients (median age 22 years, range 22 months to 84 years), all with sHLH. Amongst identifiable triggers, 43% were systemic infection, 33% rheumatological, 9% oncological. Children had predominantly a rheumatological trigger (48%), whilst adults were more commonly infection-driven (50%). Overall, rheumatologically triggered disease showed greater survival (83.3%), particularly compared with oncological triggers (42.9%). Children had a greater survival, particularly under 10 years (83%, vs. adults, 63%).
CONCLUSIONS
CONCLUSIONS
Despite IV anakinra recipients likely to be critically unwell, this cohort had similar disease triggers and survival compared to large historical cohorts, and enhances awareness of age and trigger-specific survival patterns. IV anakinra had a wide therapeutic dosing range and tolerability, regardless of trigger, demonstrating substantial utility in severe sHLH/MAS.
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
458-476Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.
Crayne C, Cron RQ. Pediatric macrophage activation syndrome, recognizing the tip of the iceberg. Eur J Rheumatol. 2020;7:13-20.
Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145-159.
Steen EA, Hermiston ML, Nichols KE, Meyer LK. Digenic inheritance: evidence and gaps in hemophagocytic lymphohistiocytosis. Front Immunol. 2021;12:777851.
Hines MR, von Bahr Greenwood T, Beutel G, et al. Consensus-based guidelines for the recognition, diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in critically ill children and adults. Crit Care Med. 2021;50:860-872.
Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2:e358-e367.
Knaak C, Schuster FS, Nyvlt P, et al. Treatment and mortality of hemophagocytic lymphohistiocytosis in adult critically ill patients: a systematic review with pooled analysis. Crit Care Med. 2020;48:e1137-e1146.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503-1516.
Henter J-I, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-131.
Ravelli A, Minoia F, Davì S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation. Arthritis Rheumatol. 2016;68:566-576.
Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130:2728-2738.
Electronic Medicines Compendium. Kineret 100 mg solution for injection in a pre-filled syringe-summary of product characteristics (SmPC). emc. Accessed June 4, 2020. https://www.medicines.org.uk/emc/product/559
Kone-Paut I, Cimaz R, Herberg J, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev. 2018;17:768-774.
Ferrara G, Giani T, Caparello MC, Farella C, Gamalero L, Cimaz R. Anakinra for treatment-resistant Kawasaki disease: evidence from a literature review. Paediatr Drugs. 2020;22:645-652.
Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64:630-633.
Dagan A, Langevitz P, Shoenfeld Y, Shovman O. Anakinra in idiopathic recurrent pericarditis refractory to immunosuppressive therapy; a preliminary experience in seven patients. Autoimmun Rev. 2019;18:627-631.
Schwier NC, Hale GM, Davies ML. Treatment of adults with idiopathic recurrent pericarditis: novel use of immunotherapy. Pharmacotherapy. 2017;37:305-318.
Aouba A, Baldolli A, Geffray L, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020;79:1381-1382.
Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325-e331.
Iglesias-Julián E, López-Veloso M, De-la-Torre-Ferrera N, et al. High dose subcutaneous anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. J Autoimmun. 2020;115:102537.
Ghuman A, Kumar K, Singh A. The use of intravenous anakinra in the treatment of secondary haemophagocytic lymphohistiocytosis (HLH): a case series. Rheumatology. 2019;58:kez110.046. doi:10.1093/rheumatology/kez110.046
Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2020;72:326-334.
NHS England. Clinical Commissioning Policy: Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages [210701P] (1924). 2021 Accessed May 13, 2022. https://www.england.nhs.uk/wp-content/uploads/2021/10/1924-Clinical-commissioning-policy-anakinra-for-haemophagocytic-lymphohistiocytosis-.pdf
Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994;271:1836-1843.
Opal SM, Fisher CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25:1115-1124.
Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44:275-281.
Karakike E, Dalekos GN, Koutsodimitropoulos I, et al. ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients. J Innate Immun. 2022;14:218-228.
Kavirayani A, Charlesworth JEG, Segal S, et al. The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH. Lancet Rheumatol. 2020;2:e736-e738.
Pontali E, Volpi S, Antonucci G, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol. 2020;146:213-215.
Meneghel A, Martini G, Amigoni A, Pettenazzo A, Padalino M, Zulian F. Case report: life-threatening macrophage activation syndrome with fulminant myocarditis successfully rescued by high dose intravenous anakinra. Front Pediatr. 2021;8:635080.
Galea J, Ogungbenro K, Hulme S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab. 2011;31:439-447.
Clark SR, McMahon CJ, Gueorguieva I, et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab. 2008;28:387-394.
Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in new York City. JAMA. 2020; published online June 8.;324:294-296. doi:10.1001/jama.2020.10374
Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324:259-269.
Wampler Muskardin TL. Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019. ACR Open Rheumatol. 2020;2:283-285.
Chou RC, Dinarello CA, Ferry JA, Cin PD. A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia. Arthritis Care Res. 2010;62:128-136.
Nigrovic LE, Shah SS, Neuman MI. Correction of cerebrospinal fluid protein for the presence of red blood cells in children with a traumatic lumbar puncture. J Pediatr. 2011;159:158-159.
Loh NK, Lucas M, Fernandez S, Prentice D. Successful treatment of macrophage activation syndrome complicating adult still disease with anakinra. Intern Med J. 2012;42:1358-1362.
Acker WB, Nixon SL, Lee JJ, Jacobson NA, Haftel H, Farley FA. Septic arthritis of the hip in the setting of hemophagocytic lymphohistiocytosis: a case report. JBJS Case Connect. 2015;5:e69.
Kemps M, Verhave JC, Claassen MAA, Ruinemans-Koerts J, van der Spek E. The case | a patient with antineutrophil cytoplasmic antibody-positive vasculitis on treatment with fever and leucopenia. Kidney Int. 2017;92:775-776.
Kavirayani A, Kadambari S, Basu-Roy R, Segal S, Qureshi A, Bailey K. Life-threatening MAS with neurological involvement responding to very high dose IV anakinra. Pediatr Rheumatol. 2018;16:52. doi:10.1186/s12969-018-0265-6
Kavirayani A, Basu-Roy R, Kadambari S, et al. Life-threatening macrophage activation syndrome with neurological involvement responding to very high dose IV anakinra. Rheumatology. 2018;57:key273.029. doi:10.1093/rheumatology/key273.029
Charlesworth JEG, Wilson S, Qureshi A, et al. Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill children. Pediatr Blood Cancer. 2021;68:e29102. doi:10.1002/pbc.29102
Shabbir S, Al-Abdulla A, Kinderlerer A, et al. Off-licence use of anakinra in critically ill adults with suspected haemophagocytosis-a single centre experience. Ann Rheum Dis. 2019;78:292-293.
Hutchinson M, Youngstein TAB, Sohal M, et al. Steroid-free management of life-threatening haemophagocytic lymphohistiocytosis in the context of suspected lymphoproliferative disease and infection. Rheumatology. 2019;58:kez108.047. doi:10.1093/rheumatology/kez108.047
Clark KEN, Collas O, Lachmann H, Singh A, Buckley J, Bhagani S. Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series. Rheumatol Adv Pract. 2020;4:rkaa040.
Dimopoulos G, de Mast Q, Markou N, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic Lymphohistiocytosis. Cell Host Microbe. 2020;28:117-123.e1.
Meneghel A, Martini G, Zulian F, Amigoni A, Pettenazzo A, Padalino M. Life-threatening macrophage activation syndrome with fulminant myocarditis successfully rescued by high dose intravenous anakinra. Pediatr Rheumatol. 2020;18:82. doi:10.1186/s12969-020-00470-5
Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. 2020;2:276-282.
Sánchez-Martín M, Laplaza M, San-Román-Pacheco S, González-Martínez B, Pérez-Martínez A, De La Oliva P. Weathering the cytokine storm: anakinra for car-T related hemophagocytic lymphohistiocytosis in a child. Pediatr Crit Care Med. 2021;22:352.
Jones N, Zelko V, Meredith C, et al. Delayed marrow engraftment as an atypical presentation of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2021;68:s139.
Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol. 2021;19:98.
Flower L, Laundy N, Khosravi M, et al. Haemophagocytic lymphohistiocytosis secondary to COVID-19: a case series. Lancet Rheumatol. 2021;3:e744-e747.
Bracaglia C, Pecoraro R, Pires Marafon D, et al. Mortality and clinical response to treatment in children with secondary hemophagocytic lymphohistiocytosis (SHLH). Pediatr Rheumatol. 2021;19:O25.
Adamski J, Jäschke B, Nieminem T, Weigl W. Bowel perforation during haemophagocytic lymphohistiocytosis treatment with corticosteroids and anakinra. Eur J Case Rep Intern Med. 2021;8:002759.
Reiff DD, Zhang M, Smitherman EA, et al. A rare STXBP2 mutation in severe COVID-19 and secondary cytokine storm syndrome. Life. 2022;12:149.
Cloyd C, Sargel C. Anakinra dosing for macrophage activation syndrome during continuous renal replacement therapy. Crit Care Med. 2022;50:504.
Stewart JA, Price T, Moser S, Mullikin D, Bryan A. Refractory macrophage activation syndrome secondary to anti-mda5 antibody positive juvenile dermatomyositis. Pediatrics. 2022;149:981.
Stubbs LA, Szafron V, Forbes LR, et al. Severe pediatric COVID-19 pneumonia treated with adjuvant anakinra. Hosp Pediatr. 2022;12:e162-e170.
Bindoli S, Galozzi P, Doria A, Sfriso P. Intravenous anakinra to curb cytokine storm in adult-onset Still's disease and in macrophage activation syndrome: a case series. Joint Bone Spine. 2023;90:105524.
Office for National Statistics, UK, NHS Digital. Health Survey for England, 2019: Data tables. 2020 Accessed October 15, 2021. https://files.digital.nhs.uk/DE/D1D9C5/HSE19-Overweight-obesity-tab.xlsx
Gregory J, Greenberg J, Basu S. Outcomes analysis of children diagnosed with hemophagocytic lymphohistiocytosis in the PICU. Pediatr Crit Care Med. 2019;20:e185-e190.
Chen T-Y, Hsu M-H, Kuo H-C, Sheen J-M, Cheng M-C, Lin Y-J. Outcome analysis of pediatric hemophagocytic lymphohistiocytosis. J Formos Med Assoc. 2021;120:172-179.
Simon AC, Delhi Kumar CG, Basu D, Ramesh Kumar R. Hemophagocytic lymphohistiocytosis in children: clinical profile and outcome. J Pediatr Hematol Oncol. 2020;42:e281-e285.
Martis N, Audemard-Verger A. Intravenous anakinra for cytokine storm syndromes. Lancet Rheumatol. 2020;2:e522.
Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall R. Intravenous anakinra for cytokine storm syndromes-authors' reply. Lancet Rheumatol. 2020;2:e522-e523.
Leventogiannis K, Kyriazopoulou E, Antonakos N, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med. 2022;3:100817.
Gómez H, Anderko RR, Carcillo JA. Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis. Cell Rep Med. 2022;3:100823.
Audemard-Verger A, Le Gouge A, Pestre V, et al. Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: a randomized controlled trial. PLoS ONE. 2022;17:e0269065.
Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E, et al. Efficacy and safety of anakinra plus standard of care for patients with severe COVID-19: a randomized phase 2/3 clinical trial. JAMA Netw Open. 2023;6:e237243.
Saag KG, Khanna PP, Keenan RT, et al. A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol. 2021;73:1533-1542.
Declercq J, Van Damme KFA, De Leeuw E, et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respir Med. 2021;9:1427-1438.
CORIMUNO-19 Collaborative Group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9:295-304.
Dember LM, Hung A, Mehrotra R, et al. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney Int. 2022;102:1178-1187.
Kharazmi AB, Moradi O, Haghighi M, et al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19. Immun Inflamm Dis. 2022;10:201-208.
Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2011:CD008794.
Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130:5942-5950.
Della Paolera S, Valencic E, Piscianz E, et al. Case report: use of anakinra in multisystem inflammatory syndrome during COVID-19 pandemic. Front Pediatr. 2021;8:624248.
Schimke LF, Marques AHC, Baiocchi GC, et al. Severe COVID-19 shares a common neutrophil activation signature with other acute inflammatory states. Cell. 2022;11:847.
Quan C, Li C, Ma H, Li Y, Zhang H. Immunopathogenesis of coronavirus-induced acute respiratory distress syndrome (ARDS): potential infection-associated hemophagocytic lymphohistiocytosis. Clin Microbiol Rev. 2020;34:e00074-20.
McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19:102537.
Reiff DD, Cron RQ. Performance of cytokine storm syndrome scoring systems in pediatric COVID-19 and multisystem inflammatory syndrome in children. ACR Open Rheumatol. 2021;3:820-826.
Liu JM, Chi J. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis? Exp Biol Med. 2022;247:330-337.